BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor
13:57 EDT 17 Aug 2012 | Elsevier Business Intelligence
At the Canaccord Genuity Global Growth Conference, the rare disease-focused biotech reiterated its goal to reach profitability in the near future with five pipeline programs potentially augmenting a portfolio of four marketed products.
Original Article: BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor
More From BioPortfolio on "BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
